Percheron Therapeutics Ltd Total Liabilities
Percheron Therapeutics Ltd total liabilities. Based on the latest financial reports, Percheron Therapeutics Ltd (PER) has total liabilities worth AU$2.43 Million AUD (≈ $1.72 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Percheron Therapeutics Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Percheron Therapeutics Ltd (2001–2025)
Total liabilities of Percheron Therapeutics Ltd from 2001 to 2025. This chart illustrates how Percheron Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Percheron Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Percheron Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
N. Leventeris S.A.
AT:LEBEK
|
Greece | €4.09 Million |
|
Nrgene Technologies Ltd
TA:NRGN
|
Israel | ILA5.12 Million |
|
Tri Banyan Tirta Tbk
JK:ALTO
|
Indonesia | Rp641.88 Billion |
|
Jeffs' Brands Ltd
NASDAQ:JFBR
|
USA | $14.82 Million |
|
Limas Indonesia Makmur Tbk
JK:LMAS
|
Indonesia | Rp162.88 Billion |
|
Socket Mobile Inc
NASDAQ:SCKT
|
USA | $9.99 Million |
|
Baronsmead Venture Trust Plc
LSE:BVT
|
UK | GBX1.18 Million |
|
Site Group International Ltd
AU:SIT
|
Australia | AU$11.23 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Percheron Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Percheron Therapeutics Ltd total assets.
Liquidity & Leverage Metrics
Percheron Therapeutics Ltd Total Liabilities Ratios Explained
Percheron Therapeutics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Percheron Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Percheron Therapeutics Ltd (2001–2025)
The table below shows the annual total liabilities of Percheron Therapeutics Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$2.43 Million ≈ $1.72 Million |
-52.93% |
| 2024-06-30 | AU$5.17 Million ≈ $3.66 Million |
+80.21% |
| 2023-06-30 | AU$2.87 Million ≈ $2.03 Million |
+121.38% |
| 2022-06-30 | AU$1.30 Million ≈ $916.45K |
+1.74% |
| 2021-06-30 | AU$1.27 Million ≈ $900.78K |
+55.02% |
| 2020-06-30 | AU$821.23K ≈ $581.07K |
-7.61% |
| 2019-06-30 | AU$888.84K ≈ $628.91K |
+53.02% |
| 2018-06-30 | AU$580.86K ≈ $411.00K |
-15.28% |
| 2017-06-30 | AU$685.65K ≈ $485.14K |
-8.60% |
| 2016-06-30 | AU$750.20K ≈ $530.82K |
+29.03% |
| 2015-06-30 | AU$581.44K ≈ $411.41K |
+2.16% |
| 2014-06-30 | AU$569.13K ≈ $402.70K |
+2.71% |
| 2013-06-30 | AU$554.10K ≈ $392.06K |
+30.90% |
| 2012-06-30 | AU$423.29K ≈ $299.50K |
+1.33% |
| 2011-06-30 | AU$417.74K ≈ $295.58K |
-11.39% |
| 2010-06-30 | AU$471.43K ≈ $333.56K |
-55.60% |
| 2009-06-30 | AU$1.06 Million ≈ $751.24K |
-69.93% |
| 2008-06-30 | AU$3.53 Million ≈ $2.50 Million |
+73.73% |
| 2007-06-30 | AU$2.03 Million ≈ $1.44 Million |
+529.17% |
| 2006-06-30 | AU$323.03K ≈ $228.56K |
-9.70% |
| 2005-06-30 | AU$357.72K ≈ $253.11K |
-64.87% |
| 2004-06-30 | AU$1.02 Million ≈ $720.40K |
+179.40% |
| 2003-06-30 | AU$364.40K ≈ $257.84K |
-80.33% |
| 2002-06-30 | AU$1.85 Million ≈ $1.31 Million |
+3301.59% |
| 2001-06-30 | AU$54.46K ≈ $38.53K |
-- |
About Percheron Therapeutics Ltd
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more